- Men with non-metastatic castration-resistant prostate cancer (nmCRPC) receiving NUBEQA plus androgen deprivation therapy (ADT) had a statistically significant improvement in its secondary endpoint of overall survival (OS) compared to placebo plus ADT (HR=0.69, 95% CI 0.53-0.88; p=0.003)1
- Updated results on secondary endpoints also show that NUBEQA delayed the time to pain progression, time to first initiation of treatment with cytotoxic chemotherapy, and time to first symptomatic skeletal event (SSE)1
- This OS improvement was achieved despite 56% of patients (309 of 554) taking placebo receiving subsequent NUBEQA or other life-prolonging therapy after the trial was unblinded1
- Any grade treatment-emergent adverse events at final analysis were generally consistent with the primary analysis of the Phase III ARAMIS trial1,2
San Francisco, CA (UroToday.com) — The New England Journal of Medicine published the full overall survival (OS) results from the pre-specified final OS analysis of the Phase III ARAMIS trial for NUBEQA® (darolutamide) in men with non-metastatic castration-resistant prostate cancer (nmCRPC).1 These data were also presented as part of the American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program, held in May 2020.